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Available online 13 January 2012Three clonal subpopulations of DLKP, a poorly differentiated squamous lung carcinoma cell line,
display striking differences in ability to survive in suspension (anoikis resistance). DLKP-SQ is
anoikis resistant (7.5% anoikis at 24 h). In contrast, DLKP-M and DLKP-I are sensitive to anoikis
(49.2% and 42.6% respectively). DLKP-I shows increased apoptosis consistently over all time
points tested while DLKP-M appear to slow down metabolically and perhaps delays onset of anoi-
kis by undergoing autophagy. Expression microarray analysis identified pronounced differential
expression of Olfactomedin 3 (OLFM3) between the clones. High expression of OLFM3 was con-
firmed at the RNA level by qRT-PCR in DLKP-SQ and at the protein level by Western blotting
(within the cell and secreted). Little or no OLFM3 was detected in the other two clones (DLKP-
M and DLKP-I). Following siRNA knockdown of OLFM3 in DLKP-SQ, anoikis was increased 2.8-
fold to 21% which was intermediate between the anoikis levels in DLKP-SQ and DLKP-M or
DLKP-I. This knockdown correlated with increased apoptosis in suspension but not in attached
culture conditions. Addition of recombinant OLFM3 reduced anoikis in DLKP-I. This is the first in-
stance of OLFM3 being linked with anoikis resistance in a human cancer cell line.
© 2012 Elsevier Inc. All rights reserved.Keywords:
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Lung cancerIntroduction
Cellular heterogeneity within tumours could provide protection
against a changing environment, such as exposure to hypoxia or
chemotherapeutic drugs or the opportunity for invasion to a
more suitable site. Subpopulations can arise by mutation or by al-
terations in the differentiation state, such as epithelial to mesen-
chymal and mesenchymal to epithelial transitions (EMT–MET) or
by differentiating cancer stem cells [1]. Lung cancer, althoughor Cellular Biotechnology, D
enan).
dimensional; siRNA, small
r Inc. All rights reserved.the most preventable cancer, kills more people than the next top
three cancers (breast, prostate and colon) [2]. Lung cancer is
heterogeneous, consisting of two main groups: small cell lung
cancer and non-small cell lung cancer (adenocarcinoma, large
cell lung cancer and squamous cell carcinoma) and even within
these groups there is morphological, functional, genetic as well
as proteomic heterogeneity [3–5]. Subpopulations have been
found to have differences in their drug resistance profiles and /or
in their invasive potential [6,7] and this can impact critically onublin City University, Dublin, Ireland. Fax: +353 1 7005484.
interfering RNA; poly-Hema, poly-2-hydroxyethyl methacrylate; CM,
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and how they interact may provide opportunities to improve
treatment or produce new diagnostic markers.
In previous work in our laboratory, three subpopulations
(DLKP-SQ, DLKP-M and DLKP-I) of a poorly differentiated squa-
mous lung carcinoma line, DLKP, were isolated and characterised
with respect to epithelial, mesenchymal and other lung differenti-
ation markers [4]. In this paper, we explore differences in anoikis-
resistance between these clonal subpopulations, and investigate
the role of Olfactomedin-3 in regulation of anoikis-resistance.Materials and methods
Chemicals
All chemicals (unless otherwise stated), FBS, glutamine and cell
culture media were obtained from Sigma (Poole, UK). Recombi-
nant OLFM3 (cat. H00118427-P01) was obtained from Abnova
(Taiwan).
Cell lines
DLKP is a poorly differentiated human squamous carcinoma cell line
established in this laboratory [9] from which the three subclones
DLKP-SQ, DLKP-M and DLKP-I were isolated [4]. DLKP-SQ is
squamous-like, DLKP-M is mesenchymal cell-like and DLKP-I ex-
hibits an intermediate morphology. DLKP variants were maintained
in DMEM/Hams F12 (1:1) supplemented with 5% FBS and 1% L-
glutamine. MCF-7, SKBR3 and RPMI-2650 were obtained from the
ATCC. RPMI-2650tx was previously obtained by continuous expo-
sure to taxol [10]. MCF-7 and SKBR3 were maintained in RPMI-
1640 supplemented with 10% FBS and 1% L-glutamine. RPMI-2650
and RPMI-2650txl were maintained in MEM supplemented with
5% FBS and 1% L-glutamine, 1% sodium pyruvate and 1% NEAA. All
cell lines were mycoplasma negative. A frozen cell pellet of 2×106
cells of DLKP and variants was submitted to LGC Limited
(Middlesex, UK) for DNA fingerprinting. A database search of over
3000 cell lines showed no match with DLKP indicating that it was
unique and the sub-cloneswere confirmed to be derived fromDLKP.
qRT-PCR for OLFM3
Total RNA extracted from cell lysates (MirVana miRNA Isolation
Kit, cat AM1560, Applied Biosystems) were quantified using the
Nanodrop (ND-1000 spectrophotometer), reverse-transcribed
using (High capacity RNA-to-cDNA kit, cat 4387406, Ambion)
and requantified using the Nanodrop. TaqMan gene expression
experiments were performed in 20 μl reactions containing 10 μl
of TaqMan® Fast Universal Master Mix (2X), No AmpErase®
UNG, 9 μl of cDNA template (80 ng) and 1 μl of TaqMan gene ex-
pression assay (20x). The following thermal cycling specifications
were performed on the ABI 7500 Fast Real-Time PCR system (Ap-
plied Biosystems) 20 s at 95 °C and 40 cycles each for 3 s at 95 °C
and 30 s at 60 °C. Expression values were calculated using the
comparative threshold cycle (Ct) method. Briefly, this technique
uses the formula 2-delta deltaCt to calculate the expression of target
genes normalised to a calibrator sample [11]. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was selected as the endoge-
nous control.SiRNA transfection
Transfection assays were carried out with NeoFX transfection re-
agent (siPORT NeoFX, AM4511, Ambion Inc) and olfactomedin 3
validated siRNAs S26707, Ambion Inc (OLFM3(1)) and S26708,
Ambion Inc (OLFM3(2)) with scrambled control 2 (AM4613, Ap-
plied Biosystems) in OptiMEM medium (Gibco™) [12]. Cells in
log phase of growth were fed prior to setting up transfection at
the following conditions: 2×105 cells per well (in 1 ml for trans-
fection) and 2 ul NeoFX. Cells were fed after overnight exposure
to transfection with 2 ml fresh medium. The cells were allowed
to grow for three days at 37 °C and 5%CO2, over which time, micro-
scopic observations were used to look for changes in morphology
and to assess the efficiency of transfection (by looking at the
growth in kinesin control (KIF-II, Ambion, Inc). At 72 h the cells
were trypsinized, counted and anoikis assays were set up. A dupli-
cate plate was washed in PBS A and lysed with 2D lysis buffer for
protein analysis.
Western blotting
Western blotting was performed on cell lysates. Samples with 20–
30 μg of protein per well, were separated on a 12% SDS gel [13].
After Western blotting [14], blots with primary antibodies
(OLFM3 (Santa Cruz, Germany), Caspase-3 and FAK (BD, Europe,
cat 610322 and 610087), phospho-FAK and phospho-PAX (Cell
Signalling Cat 8556, 2541) or alpha-tubulin, LC3 (Sigma, cat
T6199) were incubated overnight at 4 °C. Secondary antibodies
conjugated to horse-radish peroxidase (Sigma, Poole, UK) were
detected by enhanced chemiluminesence (Luminol, Santa Cruz,
CA, USA).
Anoikis assays
The base of wells in a 24-well tissue culture plate (Costar, Cat
3524) were coated with 200 μl of poly-2-hydroxyethyl methacry-
late (poly-HEMA, 12 mg/ml dissolved in 95% ethanol, Sigma
P3932) and allowed to dry overnight. Coating was repeated. Im-
mediately before use, the coated wells were washed twice with
sterile PBS A. A 1 ml volume of cell suspension at 1x10E5 cells/
ml was added to control (no poly-HEMA) and coated wells (3
per assay). The cells were incubated for specified times at 37 °C
and 5% CO2. Three hour prior to the end of the assay, 100 μl
Almar Blue (Serotec BUF012B), an indicator dye was added. Meta-
bolically active cells convert Almar Blue (resazurin) to a fluores-
cent and colormetric indicator (resorufin). Colour development
was measured on a Bio-Tek plate reader at 570 nm with reference
wavelength of 600 nm. Alternatively at the end of the incubation,
cell viability was assessed by trypan blue exclusion dye of cells
growing in poly-HEMA coated plates. Apoptosis (Guava Nexin
cat 4500–0450) and Cell cycle analysis (Guava Cell cycle reagent
4500-0220) were assessed on a bench top flow cytometer
(Guava EasyCyte Instrument).
Collection of conditioned media
Cells were grown in 175 cm2 flasks until about 40–50% confluent.
Following extensive washing with fresh medium (no serum), cells
were grown for 72 h to generate conditioned medium (CM). The
CM was removed and centrifuged at 1000 rpm for 5 min, filter-
595E X P E R I M E N T A L C E L L R E S E A R C H 3 1 8 ( 2 0 1 2 ) 5 9 3 – 6 0 2sterilised through a 0.22 μm low-protein binding filter and con-
centrated (to 10x of the starting volume of the CM) in a Vivaspin
concentrator (Vivaspin-20, cat Vs2012) with a 5 kDa cut-off and
the retentate was filter-sterilised.
Statistics
Statistics were carried out using the Student t-test assuming a
two-tailed distribution and two samples of unequal variance.
Values of p<0.05 were considered as statistically significant.Results
Anoikis resistance in DLKP clones
The presence of ‘floaters’ (viable cells that are suspended in the
medium without the need for attachment to a surface) in sub-
confluent flasks of DLKP-SQ, suggest that either DLKP-SQ or a sub-
population of the clone could be resistant to anoikis. These floating
cells if placed in a fresh flask attach and grow in the same fashion
as DLKP-SQ. In contrast, DLKP-M and DLKP-I have very few
floaters, and most of the cells floating were dead. As a result of
these observations, the three clones were tested individually for
anoikis resistance (Fig. 1). Microscopically, DLKP-SQ in suspension
consists mostly of single cells, not forming clumps. DLKP-M and
DLKP-I had very few loose single cells and formed aggregates
which became more tightly clumped with time (Fig. 1F). When
cells were grown for prolonged periods in polyhema-coated flasks
(up to 10 passages), DLKP-SQ continued to grow with no lag-
phase, the percentage viability remained high and when seeded
in normal flasks, the cells attached and grew with the same mor-
phology as the original DLKP-SQ. DLKP-M and DLKP-I, on the
other hand, struggled and after three days showed only 42% and
56% viability respectively (data not shown).
Anoikis was measured by monitoring cell counts of attached
and suspended cells, cell growth and viability in suspension and
the Almar Blue assay (a measure of the metabolic activity of
cells). After 24 h in suspension, DLKP-SQ undergo only 7.5% cell
death as measured by viable cell counts and Almar Blue measure-
ments (Figs. 1A and B) and with no significant changes in cell via-
bility (Fig. 1E). At 48 h, although there is a slight reduction in
growth for suspension cells compared to attached cells and
Almar Blue measurement, there is no change in viability. While
Annexin V staining suggest some apoptosis is occurring (Fig. 2A),
DLKP-SQ is the only clone that continues to grow in suspension
(Fig. 1D). These results suggest that no significant adaptation is re-
quired to survive anoikis conditions and that the bulk DLKP-SQ
population rather than a sub-population is anoikis resistant.
The clones, DLKP-I and DLKP-M, showed 42–50% anoikis by
Almar Blue measurement and show similar morphology under
anoikis conditions but variations in viable cell counts suggest dif-
ferent mechanisms.
DLKP-I maintained in suspension show a continuous loss of via-
ble cell numbers and viability (Figs. 1A, D–E) over time which is
reflected in the metabolic state of the cells (Figs. 1B–C) and corre-
lates with increased apoptosis. Annexin V staining revealed DLKP-
I cells to be more susceptible to apoptosis under normal attached
conditions (at 13%, higher than DLKP-SQ or DLKP-M at 6% and 8%
respectively). In suspension, there was a significant (2.8-fold)increase in apoptosis in DLKP-I, with 33% of the cells being apopto-
tic at 24 and 48 h (Fig. 2B). Procaspase-3 levels were reduced in
DLKP-I in suspension due to cleavage, indicating apoptosis
(Fig. 2C). In addition there is a loss of phosphorylated FAK and
phosphorylated Paxillin when DLKP-I are maintained in suspension
(Fig. 2C).
For DLKP-M, there was a lag phase between the loss of meta-
bolic activity and the reduction in viable cell number (Figs. 1A–
C). While there was a slight increase in annexin V staining
(Fig. 2B) this was not significant.
We analysed cell cycle progression to see if this could explain
the lag phase. For the clones, cell cycle analysis revealed some
changes between the clones under attached conditions, notably
for DLKP-I, there was a higher proportion of cells in the G2/M
phase than the other clones. However at 24 h, comparison of sus-
pension cells to attached cells for each of the clones showed no
significant differences, suggesting for this time point, cell cycle
analysis was not a determining factor in the lag phase for DLKP-
M (Fig. 2A). At 48 h, there was a more distinct increase in the pro-
portion of DLKP-M cells in G0/G1 arrest (Fig. 2A).
At 24 h, an increase in the ratio the LC3-II to LC3-I peptides of
the autophagymarker LC3 was observed (Fig. 2C). This in conjunc-
tion with the Almar Blue measurements and viable cell counts
suggests that DLKP-M may be undergoing autophagy under anoi-
kis conditions during the first 24 h.
Olfactomedin 3 in DLKP clones
Microarray analysis of the three clones of DLKP (Helena Joyce and
Padraig Doolan, unpublished results) shows that one of the most
highly differentially expressed mRNA among the clones was olfacto-
medin 3. The levels of OLFM3 in DLKP-I were 6% of those in DLKP-SQ
(p-value <0.002) and in DLKP-M were less than 1% of those in
DLKP-SQ (p-value<0.003)(Fig. 3A). Other members of the olfacto-
medin family (OLFM1, 2 and 4) were not differentially or highly
expressed in the three clones at the mRNA level from microarray
studies. Quantitative RT-PCR was carried out on the clones
(Fig. 3B) using GAPDH as the internal control (shown not to be dif-
ferentially expressed on the mRNA level in microarray results).
OLFM3 was shown to be highly expressed in the DLKP-SQ compared
to the two clones DLKP-M and DLKP-I. The levels of OLFM3 in DLKP-I
were 3.6% of those in DLKP-SQ (p-value 2x10E-13) and in DLKP-M,
were less than 1% of those in DLKP-SQ (p-value<2x10E-12).
Western blotting demonstrated high levels of OLFM3 protein
in the DLKP-SQ cells, with little or no expression in the other
two clones (Fig. 3C). Densitometry of Western blots for OLFM3
using alpha-tubulin as the loading control (shown not to be differ-
entially regulated at least at transcript level in the microarray
data) revealed DLKP-M and DLKP-I to express 1.3% and 1.2% of
the OLFM3 expressed in DLKP-SQ (p-values <0.005) (Fig. 3D).
OLFM3 is a secreted protein and may be present in the condi-
tioned media (CM). Western blotting showed expression of
OLFM3 in DLKP-SQ CM and none in DLKP-M or DLKP-I (Fig. 3E).
There was little or no alpha- tubulin in the CM, indicating a lack
of intracellular contaminants.
RNAi downregulation of Olfactomedin 3 in DLKP-SQ
Two validated siRNAs targeting OLFM3 were selected (OLFM3(1)
and OLFM3(2)) and DLKP-SQ in log phase of growth were
Fig. 1 – Effect of anoikis conditions on cell growth, Almar blue measurements, viability and morphological differences in DLKP
clones (DLKP-SQ, DLKP-I and DLKP-M). (A) Anoikis measured as the percentage of cell death when grown in polyhema-coated wells
over a 24 hour period (n=4) compared to control cells in untreated wells. B and C show the results of Almar Blue measurements at
24-hour and 48-hour in polyhema-coated versus control plates respectively. * or ** indicates a p-value of <0.05 or <0.01 comparing
DLKP-SQ to either of the other two clones; ph indicates in polyhema-coated wells. D shows the Viable cell number of the cells in the
polyhema-coated plates while E shows the viability of those cells. (F) Morphological differences between DLKP clones viewed under
200× magnification at 24 h and 48 h.
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Fig. 2 – Effect of growth under anoikis conditions on cell cycle and apoptosis. (A) Cell cycle analysis on DLKP clones comparing
attached versus suspension cells at 24 h and 48 h. (B) Apoptosis in DLKP clones as measured by Annexin-V staining in attached
versus suspension cells at 24 h. * indicates a p-value of <0.05 DLKP-I in suspension to DLKP-I attached. For all experiments, results
are the average of at least 3 separate repeats. (C) Western blotting of selected proteins in DLKP clones either attached (att) or in
suspension (sus).
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bled siRNA (negative) were used as controls). Microscopically,
transfection of kinesin siRNA was seen to reduce growth as would
be expected (by 90%, data not shown) indicating good siRNA trans-
fection conditions. Therewas nomorphological change in the DLKP-
SQ as visualised microscopically following OLFM3 siRNA transfec-
tion, suggesting that OLFM3was not a decisive factor in determining
the morphological differences between DLKP-SQ and the other
clones. At 72 h, cells counts (using trypan blue dye exclusion to
look at viable cell numbers) showed no significant change in the
total viable cell counts of siRNA-treated DLKP-SQ cells.
Knockdown of OLFM3 in DLKP-SQ had a significant impact on
anoikis resistance (Fig. 4A), resulting in a 2.8-fold increase in anoi-
kis compared to the scrambled control which was significant for
both siRNAs (p<0.01 and p<0.05 for OLFM3(1) and OLFM3(2) re-
spectively). Analysis of the protein levels of OLFM3 lysates in trans-
fected samples showed that levels of OLFM3were reduced by about
80% in the siRNA transfected cells (Figs. 4B and D). The level ofanoikis in DLKP-SQ transfected cells was not as high as that seen
with DLKP-M or DLKP-I suggesting that other factors may be having
an impact on anoikis resistance, or that the remaining levels of
OLFM3 are sufficient to maintain some level of anoikis resistance.
Loss of OLFM3 correlates with increased annexin V staining
(Fig. 4D) suggesting anoikis may be occurring by apoptosis.
There was no significant change in cell cycle profiles on loss of
OLFM3 following siRNA transfection (data not shown).
Effect of recombinant OLFM3 on Anoikis sensitive clones
As OLFM3 appears to have a protective role against anoikis in
DLKP-SQ, recombinant OLFM3 was tested on DLKP-I and DLKP-M
anoikis sensitive cell lines. Recombinant OLFM3 at 1 ng/ml re-
duced anoikis in DLKP-I significantly (p<0.001) by 1.9-fold but
not in DLKP-M, supporting a protective role for OLFM3 in apopto-
sis (Fig. 5). It is interesting to note that DLKP-I is the intermediate
clonal type in the interconversion of the DLKP clones. It appears to
Fig. 3 – Expression of OLFM3. (A) Normalised signal intensity for OLFM species from microarrays. Standard t-test with p-value
<0.003 compared to DLKP-SQ for DLKP-I or DLKP-M. OLFMl1 refers to OLFM-like 1. (B) Relative quantitation of OLFM3 compared to
DLKP-SQ and normalised to GAPDH by qRT-PCR. Results are the average and standard deviation for three biological repeats.
Standard t-test with p-value <2x10E-12 compared to DLKP-SQ for DLKP-I or DLKP-M. (C) Protein expression of OLFM3 and alpha
tubulin as loading control in DLKP clones with (D) densitometry normalised to alpha tubulin. Results are the average and standard
deviation for four biological repeats. ** represents Student t-test with p-value <0.002 for DLKP-SQ compared to DLKP-M and
DLKP-I. (E) Western blot of OLFM3 in conditioned medium from DLKP clones. Image shows average blots from three biological
repeats. A typical Western blot for OLFM3 in DLKP-SQ (labelled DLKP-SQ con) and control alpha tubulin is shown.
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only does not produce OLFM3 but has lost sensitivity to it.
Expression of OLFM3 in other anoikis resistant cell lines
We looked at expression of OLFM3 in number of cancer cell lines
with different anoikis resistance levels (Fig. 6). In the nasal carci-
noma, the anoikis-sensitive parent RPMI-2650 expressed little or
no OLFM3 but the taxol-resistant variant which was anoikis-
resistant expressed OLFM3. In breast cell lines, anoikis-resistant
SKBR-3 express OLFM3 while anoikis-sensitive MCF-7 does not.
These results together with the results for SQ-CM and recombi-
nant OLFM3 suggest that OLFM3 expression may have a role in
anoikis resistance.Discussion
In this work, the presence and possible role in anoikis of Olfacto-
medin 3 was investigated in clones of a poorly differentiatedsquamous lung carcinoma cell line. Affymetrix expression micro-
array studies in our laboratory showing OLFM3 to be one of the
most highly differentially expressed mRNAs between the DLKP
clones DLKP-SQ (high) and DLKP-M and DLKP-I (both low) were
confirmed by qRT-PCR. Western blotting confirmed the presence
of OLFM3 at the protein level in DLKP-SQ while the two other
clones had little or no expression of OLFM3.
SiRNA knockdown of OLFM3 showed no effect on total viable
cell growth or in morphology in the siRNA-transfected DLKP-SQ
compared to the parental DLKP-SQ. Knockdown of OLFM3
resulted in increased anoikis (which is a form of cell death result-
ing from a disruption in the ECM signals). Knockdown of OLFM3
did not alter cell cycle but showed increased apoptosis as mea-
sured by annexin V expression (Fig. 4D). While the knockdown
of OLFM3 was significant as detected by Western blotting
(Fig. 4), the level of anoikis in the siRNA-transfected cells was
still less than that observed in the DLKP-M or DLKP-I cells, sug-
gesting that reduction in OLFM3 levels was not sufficiently com-
plete for the time period or that other factors are involved in
anoikis resistance in DLKP-SQ compared to DLKP-M and DLKP-I.
Fig. 4 – Effect of siRNA knockdown on anoikis in DLKP-SQ cells. After siRNA transfection and growth for 72 h, cells were trypsinised
and set up under anoikis conditions, allowed to grow for a further 24 h and then counted. Samples were taken for Western blotting
at 72 h. (A) Effect of siRNA knock-down on anoikis in DLKP-SQ asmeasured using Almar blue assay. (B)Western blotting for OLFM3
expression of siRNA-transfected DLKP-SQ and (C) Densitometry of Western blot. (D) Apoptosis assay as measured by Annexin V
staining. Results are the average of at least 3 separate experiments. ** denotes Student t-test with a p-value of <0.005 compared to
the scrambled control.
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sion, anoikis was significantly reduced (Fig. 5). This is the first
time, to our knowledge, that OLFM3 has been linked with anoikis
resistance.
Olfactomedin 3 belongs to a family of glycoproteins containing
a conserved C terminal olfactomedin domain, with four main
groups OLFM1 to OLFM4 and at least 13 isoforms in mammals
[15,16]. Identified first in the olfactory neuroepithelium of the
bull frog in the 1990s [17], olfactomedins have been found in di-
verse species ranging from C. elegans to humans. The fact that
the olfactomedins have been identified only in multicellular or-
ganisms suggests that they play a role in cell–cell interaction and
signalling. Olfactomedins are involved in normal development
and are associated with several diseases including open-angle
glaucoma and cancer [18–22]. OLFM1 and 3 are expressed mainly
in the brain, OLFM2 in the pancreas and prostate, and OLFM4 in
the bone marrow, small intestine, colon and prostate [15]. Al-
though originally identified in neural tissue, OLFM3 expression
has been reported in the lung and spinal cord [23–25] and com-
mercially available OLFM3 antibodies have been shown to stainlung cancer tissue. Lung cancers have also been observed to ex-
press OLFM1 and OLFM4 [19,22]. In this study, we also observed
OLFM3 expression in lung as well as breast and nasal cancer cell
lines that were anoikis resistant. None of the other olfactomedin
proteins were differentially regulated at the mRNA level and sub-
sequently were not investigated.
OLFM3, first identified in rat eye tissue and named optimedin
[24] is a very conserved protein. OLFM3 forms homodimers (N-
terminal important) and heterodimers (C-terminal important)
with other olfactomedin domain containing proteins. OLFM3 is
often localised to the Golgi and is a secreted protein. In mouse
lens, the Pax6 transcription factor directly targets OLFM3 expres-
sion [25]. However, while Pax6 was detected in our microarray
studies, the mRNA levels were slightly lower in DLKP-SQ than in
DLKP-I or DLKP-M.
Olfactomedin 3 is known to interact with myocilin, a protein
with cytoskeletal function and is associated with hereditary
juvenile-onset open-angle glaucoma [26]. Microarray analysis
showed very low levels of myocilin mRNA to be expressed in the
clones and no difference was seen in the expression levels.
Fig. 5 – Effect of recombinant OLFM3 on DLKP-I and DLKP-M.
Results are the average of at least 3 separate experiments.
** denotes Student t-test with a p-value of <0.001 compared to
DLKP-I.
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increased growth rate [27], and modulated cytoskeletal organisa-
tion, cell adhesion and migration [15]. Expression of OLFM3 in
PC cells increased expression of N-cadherin, alpha-catenin and
beta-catenin [27]. When Lee and Tomerav [27] knocked down ex-
pression of N-cadherin in OptH cells, the decreased levels of N-
cadherin led to beta-catenin destabilisation, reduced formation
of aggregates and increased the number of single cells in culture.Fig. 6 – Correlation of expression of OLFM3 in anoikis resistant
and anoikis sensitive pairs. Results for anoikis are the average
of at least 3 separate experiments. Western blots shown are
representative of three separate repeats with alpha tubulin
being used as the loading control.Interestingly, for DLKP-SQ which express OLFM3 but not N-
cadherin (unpublished), the cells readily grow as single cells in
suspension.
While the functions of OLFM3 are mostly unknown, several of
the other olfactomedin proteins show similarities to the effects
seen with DLKP-SQ. Both OLFM1 and OLFM4 have been implicated
in apoptosis. Mutations in OLFM1 [28] and silencing of OLFM1
resulted in increased apoptosis [29]. OLFM4 may have differing
roles depending on the tissue, being antiapoptotic in gastric can-
cers [30] and growth promoting in pancreas and lung cancer
cells [31,21]. Recently, OLFM4 in prostate cancer, suppressed
growth and metastasis and exerted a negative impact on autop-
hagy through interactions with Cathepsin D and stromal-derived
factor 1 [31].
The mechanism by which OLFM3 may regulate anoikis in
DLKP-SQ is currently being investigated. Anoikis, meaning ‘home-
lessness’ in Greek, describes the induction of programmed cell
death due to inappropriate expression of or loss of cell surface at-
tachment to the extracellular matrix, and as such, provides a
mechanism for preventing dissemination of cancer cells. There
are two major cell death pathways involved in anoikis, apoptosis
and autophagy [32]. Apoptosis from the literature appears as the
main mechanism of anoikis with autophagy becoming important
where apoptosis is blocked as a means of cell death. In autophagy,
macromolecules and organelles especially mitochondria are
targeted for degradation by lysozymal proteins to recycle
nutrients within the cell. As such, autophagy may be a self-
conservation response in times of stress. If the stress is excessive,
autophagy can lead to cell death and there is extensive cross-talk
between the two processes [32].
Mechanisms of anoikis resistance include augmentation of
anti-apoptotic signals (such as Bcl-2 or Bcl-Xl [33]) or dampening
of extracellular signals. Reducing extracellular signals occur at sev-
eral levels, through cell surface receptors (such as integrins, cad-
herins and IGF-IR [34–37]), through the signalling cascades
emanating from those receptors (such as the PI3K/Akt and ERK
signalling pathways) and through the signalling molecules con-
necting receptors to pathways (such as Src family kinases and
FAK [38]). EMT has been linked to suppression of anoikis via de-
pletion of E-cadherin and expression N-cadherin to protect cells
against anoikis [39,40].
It is possible that the activity of OLFM3 in reducing anoikis in
DLKP-SQ is related to intracellular interaction with apoptotic ma-
chinery within the cell. For example, OLFM4 was found to interact
with and inhibit the apoptosis promoting factor GRIM-19 [41]. Al-
ternatively, secreted OLFM3 may interact with cell surface recep-
tors or secreted proteins to prevent anoikis signalling. Secreted
OLFM1 interacts with the Wnt signalling system through WIF-1
to regulate apoptosis through a variety of mechanisms [42].
In the clones, phosphorylated FAK is low in DLKP-SQ and
DLKP-M suggesting reduced sensitivity to extracellular anoikis
signals (Fig. 2C). In DLKP-I, the high levels of phosphorylated
FAK in attached cells, are lost when the cells are maintained in
suspension together with a loss of phosphorylated Paxillin
(Fig. 2C), suggesting that integrin signalling through FAK is active
and a source of anoikis signalling in DLKP-I.
There are several interacting proteins that have been previous-
ly identified to bind to OLFM3 including N-cadherin, Pax and Myoc
[27,23,24]. Interestingly, N-cadherin is the only one of the above
connectors that is significantly differentially regulated at the
601E X P E R I M E N T A L C E L L R E S E A R C H 3 1 8 ( 2 0 1 2 ) 5 9 3 – 6 0 2mRNA level in the DLKP-clones, being up in DLKP-I and low or ab-
sent in DLKP-M and DLKP-SQ respectively (also in protein levels as
determined by Western blotting (data not shown)).
Given that recombinant OLFM3 was able to reduce anoikis in
DLKP-I but not back to the levels of DLKP-SQ and that loss of
OLFM3 did not increase anoikis in DLKP-SQ to levels seen in the
anoikis sensitive clones, suggests that other factors are involved
in anoikis resistance in addition to OLFM3. Further, that FAK is
not significantly affected by DLKP-SQ between attached and sus-
pended cells supports more than one mechanism of anoikis resis-
tance. This is not surprising as changes in apoptosis and/or
autophagy may result in anoikis resistance. For apoptosis, many
sets of molecules interact at the cell surface, inducing different
downstream signalling cascades that lead to intracellular machin-
ery controlling apoptosis [43]. In addition, the signalling mole-
cules connecting the cytoskeleton and cytoplasm to the
extracellular matrix can exhibit extensive cross-talk between the
different signalling pathways [44].
Whether the expression of OLFM3 is a common mechanism is
uncertain. Limited analysis has shown some correlation in breast
cell lines with expression detected in the anoikis resistant SKBR3
but not in the anoikis sensitive MCF-7. Similarly OLFM3 was shown
to be expressed in the anoikis resistant nasal cell line RPMI-2650-
Txl variant while not in the anoikis sensitive parent, RPMI-2650.
Recently, both OLFM1 and OLFM4 expression have been linked
to early stage lung cancer, while OLFM4 expression has also been
implicated in early stages of gastric, colon and breast cancer
[19–21]. It may be that expression of OLFM3 in DLKP-SQ reflects
an early stage cancer.
In conclusion, this paper shows that expression of OLFM3 con-
tributes to the increased anoikis resistance of DLKP-SQ and reduces
anoikis in DLKP-I by reducing apoptosis. These results suggest that
OLFM3 expression may have a role in anoikis resistance.Conflict of interest
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